Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021
with product launch anticipated in 2021
1
Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities
Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021
PXL065 Phase 2 study ongoing with completion of recruitment expected in mid-2021 and topline data readout in mid-2022
Imeglimin and PXL065 preclinical and clinical data published in peer reviewed journals; PXL770 data accepted for oral and poster presentations at an upcoming scientific conference
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
February 12, 2021 GMT
LYON, France (BUSINESS WIRE) Feb 12, 2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update.
ADVERTISEMENT
“Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo
Share:
Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations
Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors
Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). Currently available options for patients with KRAS mutant NSCLC are associated with minimal efficacy, as well as resistance and toxicity issues. Our study will further elucidate the impact of VS-6766, alone or in combination with defactinib, in overcoming these challenges to improve outco